SEARCH

SEARCH BY CITATION

References

  • 1
    Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 11511157.
  • 2
    Simonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 1993; 73: 375411.
  • 3
    Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109142.
  • 4
    Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 13431350.
  • 5
    Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991; 337: 776778.
  • 6
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 17741778.
  • 7
    Ginès P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 92: 234241.
  • 8
    Ferral H, Bjarnason H, Wegryn SA, Rengel GJ, Nazarian GK, Rank JM, Tadavarthy SM, et al. Refractory ascites: early experience in the treatment with transjugular intrahepatic portosystemic shunt. Radiology 1993; 189: 795801.
  • 9
    Claria J, Jiménez W, Arroyo V, Guarner F, López C, LaVilla G, Asbert M, et al. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats. Gastroenterology 1989; 97: 12941299.
  • 10
    Tsuboi Y, Ishikawa SE, Fujisawa G, Okada K, Saito T. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994; 46: 237244.
  • 11
    Bosch-Marcé M, Jiménez W, Angeli P, Leivas A, Clària J, Graziotto A, Arroyo V, et al. Aquaretic efficacy of the kappa opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995; 109: 217223.
  • 12
    Llovet JM, Bartoli R, Planas R, Cabré E, Jimenez W, Urban A, Ojanguren J, et al. Bacterial translocation in cirrhotic rats. Its role in the development of SBP. Gut 1994; 35: 16481652.
  • 13
    Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J. Tumor necrosis factor alpha and interleukin-6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 14921497.
  • 14
    Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in cirrhosis. Treatment and prophylaxis. Infection 1994; 22(suppl 3): 167S175S.
  • 15
    Ginès P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716724.
  • 16
    Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enriquez J, Vilardell J. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477481.
  • 17
    Earley LE. Presentation of diagnostic criteria of the hepatorenal syndrome. In: BartoliE, ChiandussiL, eds. Hepatorenal Syndrome. Padova: Piccin Medical Books, 1979: 495504.
  • 18
    Arroyo V, Epstein M, Gallus G, Gentilini P, Ring-Larsen H, Salerno F. Refractory ascites in cirrhosis. Mechanism and management. Gastroenterology Int 1989; 2: 195207.
  • 19
    Arroyo V, Ginès A, Saló J. A European survey on the treatment of ascites in cirrhosis. J Hepatol 1994; 21: 667672.
  • 20
    Czaja AJ. Chronic active hepatitis: the challenge for a new nomenclature. Ann Intern Med 1993; 119: 510517.
  • 21
    Bernardi M, Di Marco C, Trevisani F, Fornale L, Andreone P, Cursaro C, Baraldini M, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993; 105: 188193.
  • 22
    Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 1994; 14: 2334.
  • 23
    Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84: 961968.
  • 24
    Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis 1994; 14: 3543.
  • 25
    Nicholls KM, Shapiro MD, Van Putten VJ, Kluge R, Chung HM, Bichet DG, Schrier RW. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res 1985; 56: 457461.
  • 26
    Willett I, Esler M, Burke F, Leonard P, Dudley F. Total and renal sympathetic nervous system activity in alcoholic cirrhosis. J Hepatol 1985; 1: 639648.
  • 27
    Esler M, Dudley F, Jennings G, Debinski H, Lambert G, Jones P, Crotty B, et al. Increased sympathetic nervous activity and the effects of its inhibition with clonidine in alcoholic cirrhosis. Ann Intern Med 1992; 116: 446455.
  • 28
    Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence from intraneural recordings. Ann Intern Med 1991; 114: 373380.
  • 29
    Henriksen JH, Ring-Larsen H, Kanstrup IL, Christensen NJ. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984; 25: 10341043.
  • 30
    Henriksen JH, Ring-Larsen H, Christensen NJ. Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. Gut 1987; 28: 16371642.
  • 31
    Kopeke JP, Jones S, DiBona GF. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987; 252: R1019R1023.
  • 32
    DiBona GF, Herman PJ, Sawin LL. Neural control of renal function in edema-forming states. Am J Physiol 1988; 254: R1017R1024.
  • 33
    DiBona GF, Sawin LL. Role of renal nerves in sodium retention of cirrhosis and congestive heart failure. Am J Physiol 1991; 260: R298R305.
  • 34
    Rodríguez-Martínez M, Sawin LL, DiBona GF. Arterial and cardiopulmonary baroreflex control of renal nerve activity in cirrhosis. Am J Physiol 1995; 268: R117R129.
  • 35
    Saló J, Ginès A, Anibarro L, Jiménez W, Clària J, Ginès P, Rivera F, et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone and norepinephrine levels. Hepatology 1995; 22: 479487.
  • 36
    Atucha N, Cegarra M, Ramirez A, Quesada T, Garcia-Estañ J: Pressure diuresis and natriuresis in cirrhotic rats. Am J Physiol 1993; 265: G1045G1049.
  • 37
    Wong F, Blendis L. Pathophysiology of sodium retention and ascites formation in cirrhosis: role of atrial natriuretic factor. Semin Liver Dis 1994; 14: 5970.
  • 38
    Arroyo V, Claria J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14: 4458.
  • 39
    Camps J, Solá J, Arroyo V, Pérez-Ayuso RM, Gaya J, Rivera F, Rodés J. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987; 93: 498505.
  • 40
    Ginès P, Abraham W, Schrier RW. Vasopressin in pathophysio-logical states. Semin Nephrol 1994; 14: 38497.
  • 41
    Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307: 15521557.
  • 42
    Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, Rivera F, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26: 7280.
  • 43
    Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW: Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982; 96: 413417.
  • 44
    Asahina Y, Izumi N, Enomoto N, Sasaki S, Fushimi K, Marumo F, Sato C. Increased gene expression of water channel in cirrhotic rat kidneys. Hepatology 1995; 21: 169173.
  • 45
    Linas SL, Anderson RJ, Guggenheim SJ, Robertson GL, Berl T. Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int 1981; 20: 173180.
  • 46
    Kim JK, Summer SN, Howard RL, Schrier RW. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology 1993; 17: 143147.
  • 47
    Solís-Herruzo JA, González-Gamarra A, Castellano G, Muñoz-Yagüe MT. Metabolic clearance rate of arginine vasopressin in patients with cirrhosis. Hepatology 1992; 16: 974979.
  • 48
    DiBona GF. Renal neural activity in hepatorenal syndrome. Kidney Int 1984; 25: 841853.
  • 49
    Arroyo V, Ginès P, Jiménez W, Rodés J. Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis, and treatment. In: McLntyreN, BenhamouJP, BircherJ, RizettoM, RodésJ, ed. Textbook of Clinical Hepatology. Ed 1. Oxford: Oxford Medical Press, 1991: 429470.
  • 50
    Schrier RW, Neiderbeger M, Weigert A, Ginès P. Peripheral arterial vasodilation: determinant of functional spectrum of cirrhosis. Semin Liv Dis 1994; 14: 1422.
  • 51
    Henriksen JH, Ring-Larsen H, Christensen NJ. Autonomic nervous function in liver disease. In: BomzonA, BlendisLM, eds. Cardiovascular complications of liver disease. Ed 1. Boca Raton: CRC Press, 1990: 6379.
  • 52
    Solís-Herruzo JA, Durán A, Favela V, Castellano L, Madrid L, Munoz-Yagiie MT, Morillas JD, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5: 167173.
  • 53
    Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R: Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 8: 895900.
  • 54
    Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso RM, Rivera F, et al. Sympathetic nervous activity, renin-angio-tensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983; 13: 271278.
  • 55
    Rimola A, Ginès P, Arroyo V, Camps J, Pérez-Ayuso RM, Quintero E, Gaya J, et al. Urinary excretion of 6-keto-prostaglandin F1- alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986; 3: 111117.
  • 56
    Govindarajan S, Nast CC, Smith WL, Koyle MA, Daskalopoulos J, Zipser RD. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology 1987; 7: 654659.
  • 57
    Boyer TD, Zia P, Reynolds TB. Effects of indomethacin and prostaglandin Al in renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77: 215222.
  • 58
    Arroyo V, Ginès P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81: 104122.
  • 59
    Ros J, Claria J, Jimenez W, Bosch M, Angeli P, Arroyo V, Rivera F, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22: 915920.
  • 60
    Angeli P, Jimenez W, Arroyo V, Mackenzie HS, Zhang PL, Clària J, Rivera F, et al. Renal effects of endogenous natriuretic peptides receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20: 948954.
  • 61
    Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Rivera F, Navarro-lópez F, et al. Hepatic hemodynamics and the reninangiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 9299.
  • 62
    Castells A, Saló J, Planas R, Quer JC, Ginès A, Boix J, Ginès P, et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20: 584591.
  • 63
    Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 1980; 78: 10591068.
  • 64
    Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites and renal sodium retention in cirrhosis. The “overflow” theory of ascites formation. Ann N Y Acad Sci 1970; 170: 202212.
  • 65
    Kostreva DR, Castañer A, Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980; 238: R390R394.
  • 66
    Arroyo V, Ginès P. Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology 1992; 102: 10771079.
  • 67
    Karim A. Spironolactone: disposition, metabolism, pharmaco-dynamics and bioavailability. Drug Metab Rev 1978; 8: 151158.
  • 68
    Sungaila I, Bartle WR, Walker SE, DeAngelis CD, Uetrecht J, Pappas C, Vidins E. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992; 102: 16801685.
  • 69
    Funder JW. Aldosterone action. Annu Rev Physiol 1993; 55: 115130.
  • 70
    Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to Spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14: 231236.
  • 71
    Puschett JB, Winaver J. Effects of diuretics on renal function. In: WindhagerEE, ed. Handbook of Physiology, Section 8, Renal Physiology. New York: Oxford University Press, 1992: 23352406.
  • 72
    Attallah AA. Interaction of prostaglandins with diuretics. Prostaglandins 1979; 18: 369375.
  • 73
    Pinzani M, Daskalopoulos G, Laffi G, Gentilini P, Zipser RD. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 1987; 92: 294298.
  • 74
    Gerbes AL, Bertheau-Reitha U, Falkner C, Jungst D, Paumgartner G. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double-blind cross-over trial. J Hepatol 1993; 17: 353358.
  • 75
    Sherlock S, Senewiratne B, Scott A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966; 1: 10491053.
  • 76
    Strauss E, De Sa MG, Lacet CMC, Cartapatti Da Silva E, Dos Santos WR, Honain NZ, Maffei RA Jr. Standardization of a therapeutic approach for ascites due to chronic liver disease. A prospective study of 100 cases. GED 1985; 4: 7986.
  • 77
    Baerltl JM, Sancetta SM, Gabuzda GJ. Relation to acute potassium depletion to renal ammonium metabolism in patients with cirrhosis. J Clin Pharmacol 1963; 42: 696707.
  • 78
    Häussinger D. Organization of hepatic nitrogen metabolism and its relation to acid-base homeostasis. Klin Wochenschr 1990; 68: 10961101.
  • 79
    Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970; 282: 13911396.
  • 80
    Campra JL, Reynolds TB. Effectiveness of high-dose Spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Dig Dis Sci 1978; 23: 10251030.
  • 81
    Gabow PA, Moore S, Schrier RW. Spironolactone induced hy-perchloremic acidosis in cirrhosis. Ann Intern Med 1979; 90: 338340.
  • 82
    Salerno F, Badalamenti S, Tempini S, Restell B, Bruno S, Belati G, Roffi L. Repeated paracentesis and i. V. albumin infusion to treat tense ascites in cirrhotic patients. J Hepatol 1987; 5: 102108.
  • 83
    Titó LI, Ginès P, Arroyo V, Planas R, Panes J, Rimola A, Llach J, et al. Total paracentesis associated with intravenous albumin in the management of cirrhosis and ascites. Gastroenterology 1990; 98: 146152.
  • 84
    Campbell P, Blendis LM. Physiological consequences of perito-neovenous shunting (PVS) in patients with refractory ascites secondary to chronic liver disease: implications for the pathogenesis of ascites. J Clin Nutr Gastroenterol 1986; 1: 159166.
  • 85
    Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, Hoyos M, et al. Paracentesis with infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 829835.
  • 86
    Clowdus BF, Higgins JA, Rosevear JW, Summerskill WHJ. Treatment of “refractory” ascites with a new aldosterone antagonist in patients with cirrhosis. Proc Staff Meet Mayo Clin 1960; 35: 97105.
  • 87
    Franco D, Vons C, Traynor O, de Smadja C. Should portosystemic shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988; 123: 987991.
  • 88
    Eknoyan G, Martinez-Maldonado M, Yium JJ, Suki WN. Combined ascitic-fluid and furosemide infusion in the management of ascites. N Engl J Med 1970; 282: 713717.
  • 89
    Levi VG, Opolon P, Pauleau N, Caroli J. Treatment of ascites by reinfusion of concentrated peritoneal fluid: review of 318 procedures in 210 patients. Postgrad Med J 1975; 51: 564566.
  • 90
    Raju SF, Achord JL. The effect of dialytic ultrafiltration and peritoneal reinfusion in the management of diuretic resistant ascites. Am J Gastroenterol 1984; 79: 308312.
  • 91
    LeVeen HH, Christoudias G, Ip M, Luft R, Falk G, Grosberg S. Peritoneo-venous shunting for ascites. Ann Surg 1974; 180: 580590.
  • 92
    Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, Trevisani F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 156162.
  • 93
    v Frerichs T. Tratado Practice de las Enfermedades del Higado, de los Vasos Hepáticos y de las Vias Biliares. Madrid: Libreria Extranjera y Nacional, científica y Literaria, 1877, 362353.
  • 94
    Flint A. Clinical report on hydro-peritoneum based on an analysis of forty-six cases. Am J Med Sci 1863; 45: 306339.
  • 95
    Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 2: 12211225.
  • 96
    Koppel MH, Coburn JN, Mims MM, Goldtein H, Boyle H, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969; 280: 13671371.
  • 97
    Iwatsuki S, Popovtzer MM, Gorman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from hepatorenal syndrome after orthotopic liver transplantation. N Engl J Med 1973; 289: 11551159.
  • 98
    Schroeder ET, Shear L, Sancetta SM, Gabuzda JG. Renal failure in patients with cirrhosis of the liver. III Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med 1967; 43: 887896.
  • 99
    Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, Merrill JP. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49: 175185.
  • 100
    Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 1967; 46: 18941906.
  • 101
    Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma renin levels in hepatic cirrhosis. Relationship to functional renal failure. Am J Med 1970; 49: 186191.
  • 102
    Ring-Larsen H, Hesse B, Henriksen JH, Christensen NJ. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 1982; 2: 304310.
  • 103
    Helwig FC, Schulltz CB. A liver kidney syndrome. Clinical, pathological and experimental studies. Surg Gynecol Obstet 1932; 55: 570580.
  • 104
    Wilkinson S, Arroyo V, Gazzard BG, Moodie H, Williams R. Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet 1974; 1: 521524.
  • 105
    Fernández-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire J, García-Plaza A, et al. Systemic and regional hemodynamics in patients with liver cirrhosis with and without functional renal failure. Gastroenterology 1989; 97: 13041312.
  • 106
    Maroto A, Ginés P, Arroyo V, Ginés A, Saló J, Claria J, Jimenez W, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993; 17: 788793.
  • 107
    Rodés J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 1975; 51: 492497.
  • 108
    Ginès A, Escorsell A, Ginès P, Salo J, Jimenez W, Inglada L, Navasa M, et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229236.
  • 109
    Maroto A, Ginès A, Saló J, Clària J, Ginès P, Anibarro L, Jiménez W, et al. Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. Hepatology 1994; 20: 839844.
  • 110
    Schuster VL, Seldin DW. Renal Clearance. In: SeldinDW, GiebischG, eds. The Kidney: Physiology and Pathophysiology. Second Edition. New York: Raven, 1992: 943978.
  • 111
    Mandal AK, Lansing M, Fahmy A. Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis 1982; 23632374.
  • 112
    Folio A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, Rimola A, et al. Renal impairment following spontaneous bacterial peritonitis in cirrhosis. Incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 14951501.
  • 113
    Cabrera J, Arroyo V, Ballesta AM, Rimola A, Gual J, Elena M, Rodés J. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta-2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982; 82: 97105.
  • 114
    Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90: 18271833.
  • 115
    Linas SL, Schaefer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30: 736740.
  • 116
    Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9: 183190.
  • 117
    Nagy J, Bajtai G, Brasch H, Süle T, Ambrus M, Deák G, Hámori A. The role of hepatitis B surface antigen in the pathogenesis of glomerulonephritis. Clin Nephrol 1979; 12: 109116.
  • 118
    Johnson RJ, Gretch DR, Yamabe Y, Hart J, Bacchi CE, Hartwell P, Couser WG, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465470.
  • 119
    Dudley FJ, Kanel GC, Wood LJ, Reynolds TB. Hepatorenal syndrome without avid sodium retention. Hepatology 1986; 6: 248251.